Roche has secured approval from the US Food and Drug Administration (FDA) for Ocrevus Zunovo (ocrelizumab and ...

TG Therapeutics, Inc. reported a modest Q3 beat and raised the full-year net sales guidance range for Briumvi by $7.5 million ...

Roche Holdings AG's RHHBY market capitalization grew by 13.8%, spurred by the FDA’s approval of two key products, Ocrevus Zunovo for multiple sclerosis and Tecentriq Hybreza for oncology indications, ...

A new version called “Ocrevus Zunovo” was recently approved by the Food and Drug Administration and is reportedly much quicker to inject. “Not everybody has the luxury of being able to spend ...

Roche's key products like Vabysmo, Ocrevus, and Phesgo are performing well. Read why RHHBY stock looks well positioned to ...

Dubbed Ocrevus Zunovo, the under-the-skin version of the blockbuster CD20 antibody drug could represent an additional CHF 2 billion sales opportunity, Graham said during the investor call.

(WRIC) – The University of Virginia’s (UVA) health system has become one of the first in the country to administer a groundbreaking FDA-approved drug, Ocrevus Zunovo, to patients with ...

This damages the nerves and may lead to a variety of symptoms, including numbness, vision problems, muscle weakness, and ...

Roche has said it plans to UK price its latest multiple sclerosis drug Ocrevus in line with its close rival from Novartis - aiming to undercut some established rivals. Approved in Europe earlier ...

Lee-Ballou was initially denied twice by her insurance provider for Ocravus Zunovo. That’s when Genentech ... As the availability of Ocrevus Zunuvo continues to increase across the country ...

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today reported its financial and operating results ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...